SCHEMBL1637671

SCHEMBL1637671

Cc1ccc(N2CC(C(=O)O)N(C)C2=O)cn1

nearest known ligand 0.59

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 18/20 0.59
DRD3 P35462 1/20 0.41
KCNH2 Q12809 1/20 0.41
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1637519 0.85 P2RX7 (0.59) P2RX7CHRNB2CHRNA4
SCHEMBL1638008 0.83 P2RX7 (0.60) P2RX7CHRNB2CHRNA4
SCHEMBL1637480 0.83 P2RX7 (0.53) P2RX7DRD3KCNH2
SCHEMBL1637946 0.81 P2RX7 (0.56) P2RX7DRD3
SCHEMBL1637703 0.77 P2RX7 (0.54) P2RX7
SCHEMBL1636710 0.77 P2RX7 (0.57) P2RX7
SCHEMBL1635151 0.76 P2RX7 (0.59) P2RX7
SCHEMBL1637688 0.75 P2RX7 (1.00) P2RX7
SCHEMBL1637478 0.75 P2RX7 (0.59) P2RX7
SCHEMBL1635880 0.74 P2RX7 (1.00) P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932282-B2 Imidazolidine carboxamide derivatives as P2X7 modulators GLAXO GROUP LIMITED (GB) 2011-04-26 US disclosed
US-20100075968-A1 Imidazolidine Carboxamide Derivatives as P2X7 Modulators GLAXO GROUP LIMITED (GB) 2010-03-25 US disclosed
EP-2142512-A2 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS Glaxo Group Limited (GB) 2010-01-13 EP disclosed
WO-2008119825-A2 IMIDAZOLIDINE CARBOXAMIDE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2008-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075968-A1 Imidazolidine Carboxamide Derivatives as P2X7 Modulators P2RX3, P2RX7, P2RX5 P2RX7 2/4885DRD3 1804/4885KCNH2 97/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.